Cimzia
Drug
UCB, Inc.
Total Payments
$28.8M
Transactions
255,484
Doctors
24,171
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 21,347 | 3,746 |
| 2023 | $2.3M | 49,112 | 9,615 |
| 2022 | $2.4M | 43,401 | 9,480 |
| 2021 | $3.1M | 42,268 | 8,934 |
| 2020 | $4.1M | 14,412 | 4,481 |
| 2019 | $5.4M | 33,357 | 7,836 |
| 2018 | $5.2M | 27,973 | 7,468 |
| 2017 | $5.1M | 23,614 | 6,020 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.3M | 1,615 | 53.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5.6M | 3,594 | 19.3% |
| Food and Beverage | $4.7M | 245,065 | 16.2% |
| Consulting Fee | $2.5M | 1,129 | 8.8% |
| Travel and Lodging | $682,342 | 3,919 | 2.4% |
| Space rental or facility fees (teaching hospital only) | $118,450 | 64 | 0.4% |
| Education | $9,012 | 97 | 0.0% |
| Honoraria | $1,800 | 1 | 0.0% |
Payments by Type
Research
$15.3M
1,615 transactions
General
$13.6M
253,869 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease | UCB Biosciences Inc. | $2.6M | 21 |
| Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis | UCB SA | $1.4M | 0 |
| Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation | UCB GmBH | $1.3M | 0 |
| Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis | UCB, Inc. | $1.2M | 0 |
| PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS | UCB GmBH | $1.1M | 0 |
| A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo | UCB GmBH | $724,958 | 0 |
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's Disease | UCB Biosciences Inc. | $719,539 | 11 |
| MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STU | UCB SA | $674,966 | 0 |
| PHASE 3, MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN CHILDREN AND ADOLESCENTS WITH MODERATELY TO SEVERELY ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS | UCB GmbH | $562,887 | 0 |
| MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND, PLACEBO-CONTROLLED (12 17 YEARS) INCLUDING A SINGLE OPEN LABEL ARM (6 11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC STUDY PARTICIPANTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) | UCB SA | $546,384 | 0 |
| A MULTI-CENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS OF CERTOLIZUMAB PEGOL IN ADULTS WITH ACTIVE RHEUMATOID ARTHRITIS USING AN ELECTROCHEMILUMINESCENT IMMUNO-ASSAY | UCB SA | $445,493 | 0 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO- AND ACTIVE-CONTROLLED STUDY FOLLOWED BY A PLACEBOCONTROLLED MAINTENANCE PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB SA | $380,540 | 1 |
| A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF AN ELECTRO-MECHANICAL INJECTION DEVICE (E-DEVICE) FOR THE SUBCUTANEOUS SELF-INJECTION OF CERTOLIZUMAB PEGOL SOLUTION BY SUBJECTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS, ACTIVE ANKYLOSING SPONDYLITIS, ACTIVE PSORIATIC ARTHRITIS, OR MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | UCB SA | $379,611 | 0 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB SA | $338,271 | 0 |
| Certolizumab pegol (CZP) for moderate-to-severe ulcerative colitis: an open-label study | UCB SA | $315,577 | 0 |
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE | UCB, Inc. | $265,191 | 0 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS | UCB SA | $264,823 | 0 |
| Novel Quantitative MRI for Axial Spondylitis | UCB, Inc. | $259,300 | 0 |
| A POSTMARKETING, MULTICENTER, LONGITUDINAL, PROSPECTIVE, PHARMACOKINETIC, PHASE 1B STUDY IN PREGNANT WOMEN WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH CIMZIA (CERTOLIZUMAB PEGOL) | UCB SA | $208,472 | 0 |
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients with APS or SLE | UCB SA | $206,013 | 0 |
Top Doctors Receiving Payments for Cimzia
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| John Fox | — | Grand Rapids, MI | $14.7M | 1,445 |
| , MD | Gastroenterology | Rochester, NY | $259,332 | 319 |
| , D.O | Dermatology | Grand Rapids, MI | $253,656 | 338 |
| , M.D | Rheumatology | New York, NY | $229,539 | 315 |
| , M.D | MOHS-Micrographic Surgery | Douglasville, GA | $225,498 | 305 |
| , M.D | Dermatology | Chicago, IL | $223,913 | 257 |
| , MD | Rheumatology | New York, NY | $192,865 | 249 |
| , MD | Rheumatology | Minneapolis, MN | $187,996 | 280 |
| , M.D | Rheumatology | Sugar Land, TX | $179,480 | 409 |
| , M.D | Rheumatology | Santa Fe, NM | $172,642 | 283 |
| , M.D | Specialist | Nashville, TN | $166,073 | 360 |
| , MD | Rheumatology | Saint Clair Shores, MI | $140,593 | 359 |
| , MD | Rheumatology | Tustin, CA | $135,018 | 296 |
| , MD | Rheumatology | Bannockburn, IL | $124,200 | 320 |
| , MD | Rheumatology | Shreveport, LA | $123,676 | 279 |
| , DO | Dermatology | Marion, OH | $123,636 | 183 |
| , M. D | Rheumatology | Arlington, VA | $117,318 | 368 |
| , M.D | Rheumatology | Hixson, TN | $117,087 | 378 |
| , D.O | Rheumatology | Fullerton, CA | $107,620 | 280 |
| , M.D | Rheumatology | Boynton Beach, FL | $106,655 | 308 |
| , MD | Rheumatology | St Petersburg, FL | $104,608 | 232 |
| , DO | Rheumatology | Peoria, AZ | $103,669 | 302 |
| , D.O | Dermatology | Fort Worth, TX | $102,610 | 183 |
| , MD | Rheumatology | Birmingham, AL | $102,372 | 212 |
| , M.D | Clinical & Laboratory Dermatological Immunology | Ann Arbor, MI | $99,784 | 149 |
About Cimzia
Cimzia is a drug associated with $28.8M in payments to 24,171 healthcare providers, recorded across 255,484 transactions in the CMS Open Payments database. The primary manufacturer is UCB, Inc..
Payment data is available from 2017 to 2024. In 2024, $1.4M was paid across 21,347 transactions to 3,746 doctors.
The most common payment nature for Cimzia is "Unspecified" ($15.3M, 53.0% of total).
Cimzia is associated with 20 research studies, including "A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease" ($2.6M).